European Union: Intellectual Property

Navigating the UPC's evidence minefield: when confidentiality issues clash with procedural deadlines.

in our previous videos we talked how it's best to use the company a Cyprus company for your trading of cryptos and as we've explained this is because the Cyprus...

The Data Act, effective from January 11, 2024, is reshaping the digital landscape, driving competition, and innovation through enhanced data sharing.

IP rights play a pivotal role in the protection of music and maintenance of an equitable working environment for songwriters, composers and performers. Crucially, IP rights, in particular copyright...

Klauzula bestsellerowa to instytucja prawa autorskiego uregulowana w art. 44 Ustawy o prawie autorskim i prawach pokrewnych (dalej: PrAut)...

In recent months, a number of tools that allow the creation or modification of music using artificial intelligence have appeared on the market, e.g. Loudly, SongR, Soundraw, MusicGen and Suno.

In a recent ruling, a Regional Court in Poland reaffirmed that importing branded goods from the UK into the European Union (EU) without the right holder's consent constitutes a criminal offence...

Before a song finds its way into our ears, it begins quietly: a stray thought, a scribbled lyric, a single chord played in a moment of instinct.

The UPC has recently issued its first two decisions on FRAND, setting important guidelines for SEP owners and implementers.

On 9 February 2012, the Court of Justice of the European Union (the "ECJ") answered a preliminary question referred to it by the High Court of Justice of England and Wales (the "Referring Court") in Novartis AG ("Novartis") v. Actavis UK Ltd.

A recently published decision of the European Patent Office’s (EPO) Board of Appeal about European patents and clinical trials provides for interesting reading and for some important pointers about how to deal with clinical trials for medicinal products but also for medical devices as to not destroy novelty of a patentable invention with invalidity as result.

The patent of Oliver Brüstle that is at stake relates to purified neural precursor cells and to processes for their production from embryonic stem cells.